Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
72.29
-1.13 (-1.54%)
4:53:34 PM EDT: $72.30 +0.01 (+0.01%)
Products

FDA Approves Merck’S Keytruda® As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma (Rcc) Following Surgery

Published: 11/18/2021 11:57 GMT
Merck & Co Inc (MRK) - FDA Approves Merck’s Keytruda® (pembrolizumab) As Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (rcc) Following Surgery.
Merck -approval Based on Data From Phase 3 Keynote-564 Trial, in Which Keytruda Showed Statistically Significant Improvement in Disease-free Survival.